Epirubicin, Cisplatin, and Fluorouracil in Gastric and Esophageal Cancer: A Step Ahead?

This publication has 10 references indexed in Scilit:

• Prospective Randomized Trial Comparing Mitomycin, Cisplatin, and Protracted Venous-Infusion Fluorouracil (PVI 5-FU) With Epirubicin, Cisplatin, and PVI 5-FU in Advanced Esophagogastric Cancer
  Journal of Clinical Oncology, 2002
• Chemoradiotherapy after Surgery Compared with Surgery Alone for Adenocarcinoma of the Stomach or Gastroesophageal Junction
  New England Journal of Medicine, 2001
• Preoperative Chemoradiotherapy for Esophageal Cancer
  Journal of Clinical Oncology, 2001
• Chemotherapy Followed by Surgery Compared with Surgery Alone for Localized Esophageal Cancer
  New England Journal of Medicine, 1998
• Changing patterns in the incidence of esophageal and gastric carcinoma in the United States
  Cancer, 1998
• ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy.
  Journal of Clinical Oncology, 1998
• Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer.
  Journal of Clinical Oncology, 1997
• Epirubicin, cisplatin, and protracted venous infusion of 5-fluorouracil for esophagogastric adenocarcinoma: Response, toxicity, quality of life, and survival
  Cancer, 1996
• Combined Chemotherapy and Radiotherapy Compared with Radiotherapy Alone in Patients with Cancer of the Esophagus
  New England Journal of Medicine, 1992
• Sequential high-dose methotrexate and fluorouracil combined with doxorubicin--a step ahead in the treatment of advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cooperative Group.
  Journal of Clinical Oncology, 1991